CN1589853A - Compound preparation for treating mucosa ulceration - Google Patents
Compound preparation for treating mucosa ulceration Download PDFInfo
- Publication number
- CN1589853A CN1589853A CN 03154193 CN03154193A CN1589853A CN 1589853 A CN1589853 A CN 1589853A CN 03154193 CN03154193 CN 03154193 CN 03154193 A CN03154193 A CN 03154193A CN 1589853 A CN1589853 A CN 1589853A
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound preparation
- radix
- group
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004877 mucosa Anatomy 0.000 title claims abstract description 11
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 38
- 150000001875 compounds Chemical class 0.000 title claims description 11
- 230000036269 ulceration Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 16
- 231100000397 ulcer Toxicity 0.000 claims abstract description 9
- 239000009609 fructus phyllanthi Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 5
- 208000002399 aphthous stomatitis Diseases 0.000 abstract description 12
- 208000007117 Oral Ulcer Diseases 0.000 abstract description 10
- 201000007100 Pharyngitis Diseases 0.000 abstract description 4
- 235000015489 Emblica officinalis Nutrition 0.000 abstract description 2
- 244000248557 Ophiopogon japonicus Species 0.000 abstract description 2
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 206010068319 Oropharyngeal pain Diseases 0.000 abstract 1
- 240000009120 Phyllanthus emblica Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000000242 pagocytic effect Effects 0.000 description 8
- 230000008961 swelling Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 206010028034 Mouth ulceration Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 244000119298 Emblica officinalis Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001521474 Liriope <hydrozoan> Species 0.000 description 1
- 241000283956 Manis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine for treating oral ulcer, mucosa ulcer, pharyngitis and sore throat is prepared from ophiopogon root 1-99 wt% and phyllanthus emblica fruit 1-99 wt.%.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of the mucosa ulcer, particularly relating to a kind of is the pharmaceutical composition of the treatment mucosa ulcer made of raw material with the vegetable Chinese herbal medicine.
Background technology
The mucosa ulcer is a kind of common disease, be its typical case's representative with oral ulcer again wherein, the medicament of its treatment has Chinese medicine preparation, Western medicine preparation is also arranged, Chinese patent application CN1257732A discloses a kind of " Chinese patent medicine---" quick-acting aphtha spirit " capsule of treatment oral ulcer and behcets disease ", it is a kind of Chinese patent medicine for the treatment of oral ulcer and behcets disease, raw material of Chinese medicine that it is used and weight proportion are: Radix Ginseng 12-18 part, Squama Manis 3-7 part, Rhizoma Dioscoreae 8-12 part, Radix Astragali 17-23 part, Flos Lonicerae 17-23 part, Herba Menthae 17-23 part, Cordyceps 8-12 part, Cortex Cinnamomi 17-23 part, Stigma Croci 12-18 part.Chinese patent application CN1190013A discloses a kind of " ointment for toothache and stomatocase ", it is to form: Cinnabaris 8-12 part by the drug regimen that following weight is divided, Borax 8-12 part, Rhizoma Coptidis 15-20 part, Radix Et Rhizoma Rhei 13-15 part, Cortex Phellodendri 15-20 part, Radix Glycyrrhizae 15-20 part, Borneolum Syntheticum 25-30 part, Cera Flava 30-35 part, Oleum sesami 650-700 part.
Summary of the invention
It is the compound preparation of the treatment mucosa ulcer made of raw material by natural vegetable Chinese herbal medicine that purpose of the present invention is intended to provide a kind of.
The compound preparation of treatment mucosa ulcer of the present invention mainly is made up of following raw materials by weight percent medicine: Radix Ophiopogonis 1-99%, Fructus Phyllanthi 1-99%.
Also can be Radix Liriopes Radix Ophiopogonis in above-mentioned composition, and can add Radix Paeoniae Rubra 10-40%, Radix Rehmanniae 10-40%, Radix Glycyrrhizae 5-30%.
Fructus Phyllanthi of the present invention (Phyllanthus emblica) has convergence, the effect of protection mucosa, antioxidation, chromosomal aberration effect due to resisting nitrosamine mutagenesis and radiating, blood fat reducing, reduction myocardial oxygen consumption and anti thrombotic action; Radix Ophiopogonis, (Ophiopogon japonicus) had the maincenter calmness, anti-fatigue anoxia-tolerance effect, heart tonifying, arrhythmia, the effect of protection ischemic myocardium, certain bacteriostasis and hypoglycemic activity, immunological enhancement (non-specific, cell and humoral immunization); Radix Rehmanniae (Rehmannia glutinosa) has anti-radiation hepatoprotective effect, blood sugar lowering, hypocatharsis, antiobesity action, anti-inflammation detumescence, antifungal and interferon inducted effect; Radix Paeoniae Rubra (Paeonia lactiflora) has anticoagulant; antithrombotic forms and the ischemic myocardial protection effect; collaborative chemotherapeutic antitumaous effect; strengthening RE is function, antimicrobial antiphlogistic detumescence effect, immunomodulating (Ils; Th/Ts); the short IFN that induces, direct antivirus action (make vesicular stomatitis virus tire decline), spasmolytic, analgesia, sedation etc.
Compound preparation of the present invention is oral formulations such as mixture, tablet, granule, capsule, soft capsule.
Compound preparation of the present invention is mainly used in the mucosa ulcer beyond treatment oral ulcer, recurrent oral ulceration and the oral ulcer, acute and chronic pharyngitis, diseases such as laryngopharynx swelling and pain.
Preparation of the present invention through acute toxicity test and long term toxicity test, proves that this product do not have overt toxicity reaction, and is safe.
Pharmacodynamics test: animal, medicine and reagent, omissions such as strain, culture medium, instrumental method.
Method and result:
One, this preparation is to the regulating action of immune function of mice
1, to the influence of Turnover of Mouse Peritoneal Macrophages phagocytic function:
The result shows that phagocytic rate and the phagocytic index of CY group macrophage phagocytic CRBC are starkly lower than normal control group (P＜0.01).All can obviously improve phagocyte phagocytic percentage and the phagocytic index (P＜0.01) of mice under the CY immunosuppressant with the CY group than this preparation high and low dose, LMS, KOUKUILING; KOUKUILING and this preparation high dose group be there was no significant difference (P＞0.2) relatively; Variant between high low dose group (P＜0.01).Mice phagocytic function under presentation of results, this preparation suppress CY has between tangible activation, potentiation and two kinds of dosage dose-effect relationship is arranged.
2, to the influence of the inductive mouse insole delayed hypersensitivity of sheep red blood cell (SRBC) (SRBC) (DTH):
CY group footpad swelling thickness significantly is lower than NS group (P＜0.01).This preparation, KOUKUILING, LMS respectively organize footpad swelling thickness and are significantly higher than CY group (P＜0.01).Show that simultaneously effect that KOUKUILING improves DHT is than this preparation obvious (P＜0.01).
3, the influence that the mice serum hemolysin is formed:
This preparation, KOUKUILING, LMS all can strengthen the OD value (P＜0.01) that CY suppresses.KOUKUILING and this preparation (high and low dose) OD value there was no significant difference (P＞0.1).Illustrate that the humoral immunization that this preparation suppresses CY is dosage correlation enhancing facilitation, obviously improves the antibody forming capacity of spleen.
4, to the influence of mouse boosting cell con A and LPS breeder reaction:
Compare with normal group, CY has obviously suppressed T cell proliferative response (P＜0.01), each group of administration all can promote the T lymphocyte transformation that CY suppresses, make conversion ratio obviously increase (P＜0.01) and illustrate that this preparation has facilitation to the mouse cell immunologic function, simultaneously visible KOUKUILING and this preparation of low dosage OD value there was no significant difference (P＜0.01).
High and low group of this preparation and KOUKUILING all can improve the LPS breeder reaction that CY suppresses and be (P＜0.001), show simultaneously between high and low group of KOUKUILING and this preparation to act on there was no significant difference (P＞0.05).
Two, this preparation is to the inhibitory action of antibacterial
The preparation of medicine: the preparation of strain and test method are omitted.
The result shows that this preparation is respectively the MIC that is equipped with bacterium: staphylococcus aureus 112.5mg/ml; Candida albicans 56.25mg/ml.
Three, this preparation xylol causes the influence of mice auricle swelling
The preparation of medicinal liquid, test method are omitted.
The result shows: the obvious swelling thickness of control group mice auris dextra increases, and the two auricle method of double differences are bigger, and the administration group two auricle method of double differences are starkly lower than matched group.Show that this preparation height, middle dosage group and aspirin group all have the effect that suppresses swelling preferably, antiinflammatory action is obvious, and certain dose-effect relationship is arranged.
Conclusion and discussion
One, experimental result shows, this preparation has the effect of obvious antagonism CY induced mice immunologic hypofunction.Show as:
1, obviously improves the peritoneal macrophage phagocytic function of CY immunosuppressed mice.
2, the serum hemolysin due to the CY is formed suppress and delayed hypersensitivity (DTH) suppresses to have tangible promotion restitution.
3, can significantly promote CY immunosuppressed mice conA, the breeder reaction of the inductive spleen lymphocyte of LPS.
Above immune indexes synthesis result has pointed out this preparation can bring into play its regulating action when immunologic function is suppressed, and shows as immunosuppressant nonspecific immunity cytophagy and improves enhancing antibody generation, B and T lymphopoiesis.
Two, this preparation has certain bacteriostasis to the oral cavity common bacteria.
Three, this preparation has tangible resist inflammation on repercussive function.
In sum, this preparation improves immunosuppressant and many-sided regulating action and anti-inflammation detumescence and certain antibacterial action is applied to recurrent oral ulceration for it and inflammation provides the pharmacodynamic experiment foundation.
Clinical trial:
Allly meet deficiency of YIN aphtha tcm diagnosis and dialectical standard and doctor trained in Western medicine RAU diagnostic criteria person, all can include the test case in.Participate in this test through 345 routine patients, the result is that clinical cure (was promptly taken medicine 4 days, oral ulcer all heals, pain disappears, other simultaneous phenomenons also disappear) 122 examples, (promptly took medicine 4 days, the oral ulcer healing reaches more than 2/3rds produce effects, pain subtracts greatly, still simultaneous phenomenon subtracts greatly) 141 examples, progress (was promptly taken medicine oral ulcer healing less than 2/3rds 4 days, pain relief) 56 examples, invalid (promptly took medicine 4 days, no change such as oral ulcer and pain or increase the weight of) 26 examples, effective percentage 92.5%, obvious effective rate 76.2%, inefficiency 7.5%.
The specific embodiment
Embodiment 1:
Get gram Radix Ophiopogonis 400, Fructus Phyllanthi 400 grams, add water 10000ml, 8000ml, 6000ml respectively, decoct, merge three times decoction liquor, vacuum decompression concentrates, adding preservative agent and other right amount of auxiliary materials, and heat sterilization is made mixture 1000ml.
Embodiment 2:
Get gram Radix Ophiopogonis 500, Fructus Phyllanthi 800 grams, Radix Paeoniae Rubra 300 grams decoct with water twice, add 12 times in water at every turn, decocted 1.5 hours, filter, filtrate is concentrated into proportion 1.10-1.15, and adding ethanol to determining alcohol is that the 50-60% placement is spent the night, and filters, after filtrate decompression is steamed and is removed ethanol, evaporate to dryness adds adjuvant, granulates, tabletting is made 1000 in 0.35g/ tablet.
Embodiment 3:
Get Fructus Phyllanthi 300 gram, Radix Ophiopogonis 600 gram, Radix Paeoniae Rubra 300 grams, Radix Rehmanniae 600 grams.
Decoct with water secondary, add 12 times in water at every turn, filter, filtrate is by JD-(WLD), D
101, DiaionHP-20 or D
201Macroporous adsorbent resin, adsorbate be with the 10-90% ethanol elution, the eluent concentrating under reduced pressure, vacuum or spray drying are granulated, make 1000 of tablet or capsules ().
Embodiment 4:
Get Fructus Phyllanthi 600 gram, Radix Ophiopogonis 300 gram, Radix Paeoniae Rubra 300 grams, Radix Rehmanniae 400 grams, Radix Glycyrrhizae 100 grams.
Add 10-90% alcohol reflux or percolation and extract, concentrated extracting solution, extractum are made oral formulations such as mixture, tablet, granule, capsule, soft capsule.
Embodiment 5:
Get Fructus Phyllanthi 100 gram, Radix Ophiopogonis 500 gram, Radix Paeoniae Rubra 500 grams, Radix Rehmanniae 500 grams.
Press the compound recipe that different proportion is formed, adopt the extractum after embodiment 1,2,3,4 methods are extracted, made with extra care, make oral formulations such as mixture, tablet, granule, capsule, soft capsule.
Claims (4)
1, a kind of compound preparation for the treatment of the mucosa ulcer is characterized in that mainly being made up of following raw materials by weight percent medicine: Radix Ophiopogonis 1-99%, Fructus Phyllanthi 1-99%.
2, according to the described compound preparation of claim 1, it is characterized in that containing Radix Paeoniae Rubra 10-40%.
3, according to the described compound preparation of claim 1, it is characterized in that containing Radix Rehmanniae 10-40%.
4, according to the described compound preparation of claim 1, it is characterized in that containing Radix Glycyrrhizae 5-30%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031541933A CN100506260C (en) | 2003-08-28 | 2003-08-28 | Compound preparation for treating mucosa ulceration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031541933A CN100506260C (en) | 2003-08-28 | 2003-08-28 | Compound preparation for treating mucosa ulceration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1589853A true CN1589853A (en) | 2005-03-09 |
| CN100506260C CN100506260C (en) | 2009-07-01 |
Family
ID=34597952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031541933A Expired - Lifetime CN100506260C (en) | 2003-08-28 | 2003-08-28 | Compound preparation for treating mucosa ulceration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100506260C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432380A (en) * | 2013-09-05 | 2013-12-11 | 滇虹药业集团股份有限公司 | Production method of traditional Chinese medicine preparation as well as medicine produced for treating mucomembranous ulcer and determination method |
| CN104740483A (en) * | 2015-04-24 | 2015-07-01 | 高元琴 | Traditional Chinese medicine used for treating recurrent oral ulceration |
| CN107106477A (en) * | 2014-12-23 | 2017-08-29 | 高露洁-棕榄公司 | Oral care composition and application method |
| CN107281383A (en) * | 2017-07-07 | 2017-10-24 | 云南蓝钻生物科技股份有限公司 | A kind of compound pharyngitis preparation and preparation method thereof |
| CN107372999A (en) * | 2017-08-29 | 2017-11-24 | 成都中医药大学 | A kind of composition and technique of tuber of dwarf lilyturf thoat-soothing drops formula |
| CN111184809A (en) * | 2020-03-26 | 2020-05-22 | 穆棱市晟宇生物科技有限公司 | Food, health-care product or medicine composition for clearing and moistening throat and preparation method thereof |
-
2003
- 2003-08-28 CN CNB031541933A patent/CN100506260C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432380A (en) * | 2013-09-05 | 2013-12-11 | 滇虹药业集团股份有限公司 | Production method of traditional Chinese medicine preparation as well as medicine produced for treating mucomembranous ulcer and determination method |
| CN103432380B (en) * | 2013-09-05 | 2016-01-20 | 滇虹药业集团股份有限公司 | The mucosa ulceration medicine of Chinese medicine preparation production method and production thereof and assay method |
| CN107106477A (en) * | 2014-12-23 | 2017-08-29 | 高露洁-棕榄公司 | Oral care composition and application method |
| CN104740483A (en) * | 2015-04-24 | 2015-07-01 | 高元琴 | Traditional Chinese medicine used for treating recurrent oral ulceration |
| CN107281383A (en) * | 2017-07-07 | 2017-10-24 | 云南蓝钻生物科技股份有限公司 | A kind of compound pharyngitis preparation and preparation method thereof |
| CN107372999A (en) * | 2017-08-29 | 2017-11-24 | 成都中医药大学 | A kind of composition and technique of tuber of dwarf lilyturf thoat-soothing drops formula |
| CN111184809A (en) * | 2020-03-26 | 2020-05-22 | 穆棱市晟宇生物科技有限公司 | Food, health-care product or medicine composition for clearing and moistening throat and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100506260C (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1742939A (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN100506260C (en) | Compound preparation for treating mucosa ulceration | |
| CN1171952A (en) | Traditional Chinese medicine preparation for eradicating Helicobacter phlori | |
| CN1182858C (en) | Heart-nourishing tea capsule and its prepn | |
| CN105641014B (en) | Nandina total alkaloid extract and its application in preparing treatment pharyngitis drug | |
| CN1939498A (en) | Chinese-medicinal preparation for treating psoriasis | |
| CN1709415A (en) | Asparagus extract and its preparing method | |
| CN1840035A (en) | Medicinal composition for treating acute and chronic pneumonia, its preparation method and purpose | |
| CN1267086C (en) | Medicine for treating diabetes and adjusting blood sugar concentration and its preparation | |
| CN102940747B (en) | Medicine composition for treating gout | |
| CN1233364C (en) | Chinese medicine for treating digestive ulcerating sore and its preparation method | |
| CN1158091C (en) | Chinese medicine composition for treating lung cancer | |
| CN1261151C (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN1176690C (en) | Medicine for treating chronic nephritis | |
| CN1879755A (en) | Chinese medicinal composition for preparing tumor-treating medicine | |
| CN1319578C (en) | Prescription of Chinese medicine compound preparation, its preparation method and use | |
| CN1686391A (en) | Medicine for treating disease caused by heat toxin | |
| CN1255123C (en) | Clearing lung and stopping Asthma medicine and preparing process thereof | |
| CN1470271A (en) | Chinese medicinal compound preparation for treating liver fibrillation disease and its preparation method | |
| CN1042597C (en) | Vision-brighting and blood sugar decreasing composition and its produciton | |
| CN1559523A (en) | Naodesheng soft capsule and its preparation method | |
| CN1233383C (en) | Chinese medicinal preparation for treating prostate disease and its preparation method | |
| CN1150016C (en) | Medicine for treating fever caused by lupus erythematosus and other immunological disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SHANGHAI DIHON MEDICAL CO.,LTD. Assignor: KUNMING DIHON PHARMACEUTICAL Ltd. Contract fulfillment period: 2009.10.25 to 2017.10.25 Contract record no.: 2009530000048 Denomination of invention: Compound preparation for treating mucosa ulceration Granted publication date: 20090701 License type: General permission Record date: 20091202 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: COMMON LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.10.25 TO 2017.10.25; CHANGE OF CONTRACT Name of requester: SHANGHAI DIHON PHARMACEUTICAL CO., LTD. Effective date: 20091202 |
|
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN DIANHONG MEDICINE GROUP CO., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100301 Address after: 650106 No. 45, medical Road, hi tech Zone, Yunnan, Kunming Co-patentee after: YUNNAN DIHON PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: KUNMING DIHON PHARMACEUTICAL Ltd. Address before: 650106 No. 45, medical Road, hi tech Zone, Yunnan, Kunming Patentee before: KUNMING DIHON PHARMACEUTICAL Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: SICHUAN DIHON MEDICAL DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: KUNING DIANHONG PHARMACEUTICAL CO., LTD. Effective date: 20110331 Free format text: FORMER OWNER: KUNMING DIHON PHARMACEUTICAL CO., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650106 NO. 45, KEYI ROAD, HIGH-TECH. ZONE, KUNMING CITY, YUNNAN PROVINCE TO: 650107 NO. 45, KEYI ROAD, HIGH-TECH. ZONE, KUNMING CITY, YUNNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110331 Address after: 650107 No. 45, medical Road, hi tech Zone, Yunnan, Kunming Patentee after: SICHUAN DIHON MEDICAL DEVELOPMENT Co.,Ltd. Address before: 650106 No. 45, medical Road, hi tech Zone, Yunnan, Kunming Co-patentee before: YUNNAN DIHON PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: KUNMING DIHON PHARMACEUTICAL Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050309 Assignee: DIHON PHARMACEUTICAL GROUP Co.,Ltd. Assignor: SICHUAN DIHON MEDICAL DEVELOPMENT Co.,Ltd. Contract record no.: 2013510000062 Denomination of invention: Compound preparation for treating mucosa ulceration Granted publication date: 20090701 License type: Common License Record date: 20130725 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160720 Address after: 659196 No. 45, medical Road, hi tech Development Zone, Yunnan, Kunming Patentee after: DIHON PHARMACEUTICAL GROUP Co.,Ltd. Address before: 650107 No. 45, medical Road, hi tech Zone, Yunnan, Kunming Patentee before: SICHUAN DIHON MEDICAL DEVELOPMENT Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200108 Address after: 650503 1298 Bio Valley Street, majinpu, Kunming, Yunnan Patentee after: Yunnan Shengke Pharmaceutical Co.,Ltd. Address before: 659196 No. 45, medical Road, hi tech Development Zone, Yunnan, Kunming Patentee before: DIHON PHARMACEUTICAL GROUP Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20090701 |
|
| CX01 | Expiry of patent term |